Docetaxel Accord

Țară: Uniunea Europeană

Limbă: engleză

Sursă: EMA (European Medicines Agency)

Cumpara asta acum

Prospect Prospect (PIL)
08-04-2020

Ingredient activ:

docetaxel

Disponibil de la:

Accord Healthcare S.L.U.

Codul ATC:

L01CD02

INN (nume internaţional):

docetaxel

Grupul Terapeutică:

Antineoplastic agents,

Zonă Terapeutică:

Head and Neck Neoplasms, Carcinoma, Non-Small-Cell Lung, Adenocarcinoma, Prostatic Neoplasms, Breast Neoplasms

Indicații terapeutice:

Breast cancerDocetaxel Accord in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:operable node-positive breast cancer;operable node-negative breast cancer.For patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.Docetaxel Accord in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.Docetaxel Accord monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent.Docetaxel Accord in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer w

Rezumat produs:

Revision: 13

Statutul autorizaţiei:

Authorised

Data de autorizare:

2012-05-22

Prospect

                                59
B. PACKAGE LEAFLET
60
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
DOCETAXEL ACCORD 20 MG/1 ML CONCENTRATE FOR SOLUTION FOR INFUSION
DOCETAXEL ACCORD 80 MG/4 ML CONCENTRATE FOR SOLUTION FOR INFUSION
DOCETAXEL ACCORD 160 MG/8 ML CONCENTRATE FOR SOLUTION FOR INFUSION
docetaxel
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.

Keep this leaflet. You may need to read it again.

If you have any further questions, ask your doctor, hospital
pharmacist or nurse.

If you get any side effects talk to your doctor, hospital pharmacist
or nurse. This includes any
possible side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET:
1.
What Docetaxel Accord is and what it is used for
2.
What you need to know before you use Docetaxel Accord
3.
How to use Docetaxel Accord
4.
Possible side effects
5.
How to store Docetaxel Accord
6.
Contents of the pack and other information
1.
WHAT DOCETAXEL ACCORD IS AND WHAT IT IS USED FOR
The name of this medicine is Docetaxel Accord. Its common name is
docetaxel. Docetaxel is a
substance derived from the needles of yew trees.
Docetaxel belongs to the group of anti-cancer medicines called
taxoids.
Docetaxel Accord has been prescribed by your doctor for the treatment
of breast cancer, special forms
of lung cancer (non-small cell lung cancer), prostate cancer, gastric
cancer or head and neck cancer:
-
For the treatment of advanced breast cancer, docetaxel could be
administered either alone or in
combination with doxorubicin, or trastuzumab, or capecitabine.
-
For the treatment of early breast cancer with or without lymph node
involvement, docetaxel could
be administered in combination with doxorubicin and cyclophosphamide.
-
For the treatment of lung cancer, docetaxel could be administered
either alone or in combination
with cisplatin.
-
For the treatment of prostate cancer, docetaxel is administered in
combination with prednisone or
prednisolone.
-
For the treatment of metastatic gastric c
                                
                                Citiți documentul complet
                                
                            

Caracteristicilor produsului

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Docetaxel Accord 20 mg/1 ml concentrate for solution for infusion
Docetaxel Accord 80 mg/4 ml concentrate for solution for infusion
Docetaxel Accord 160 mg/8 ml concentrate for solution for infusion
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml of concentrate contains 20 mg docetaxel.
Docetaxel Accord 20 mg/1 ml concentrate for solution for infusion
One vial of 1 ml of concentrate contains 20 mg of docetaxel.
Docetaxel Accord 80 mg/4 ml concentrate for solution for infusion
One vial of 4 ml of concentrate contains 80 mg of docetaxel.
Docetaxel Accord 160 mg/8 ml concentrate for solution for infusion
One vial of 8 ml of concentrate contains 160 mg of docetaxel.
Excipient with known effect
_Docetaxel Accord 20 mg/1 ml concentrate for solution for infusion_
Each vial of 1ml of concentrate contains 0.5 ml of ethanol anhydrous
(395 mg).
_Docetaxel Accord 80 mg/4 ml concentrate for solution for infusion_
Each vial of 4ml of concentrate contains 2 ml of ethanol anhydrous
(1.58 g).
_Docetaxel Accord 160 mg/8 ml concentrate for solution for infusion_
Each vial of 8ml of concentrate contains 4 ml of ethanol anhydrous
(3.16 g).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Concentrate for solution for infusion (sterile concentrate).
The concentrate is a clear pale yellow to brownish-yellow solution.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Breast cancer
Docetaxel Accord in combination with doxorubicin and cyclophosphamide
is indicated for the
adjuvant treatment of patients with:

operable node-positive breast cancer

operable node-negative breast cancer .
For patients with operable node-negative breast cancer, adjuvant
treatment should be restricted to
patients eligible to receive chemotherapy according to internationally
established criteria for primary
therapy of early breast cancer (see section 5.1).
Docetaxel Accord in combination with doxorubicin is indicated for the
treatment of patients wi
                                
                                Citiți documentul complet
                                
                            

Documente în alte limbi

Prospect Prospect bulgară 14-09-2023
Caracteristicilor produsului Caracteristicilor produsului bulgară 14-09-2023
Raport public de evaluare Raport public de evaluare bulgară 08-04-2020
Prospect Prospect spaniolă 14-09-2023
Caracteristicilor produsului Caracteristicilor produsului spaniolă 14-09-2023
Raport public de evaluare Raport public de evaluare spaniolă 08-04-2020
Prospect Prospect cehă 14-09-2023
Caracteristicilor produsului Caracteristicilor produsului cehă 14-09-2023
Raport public de evaluare Raport public de evaluare cehă 08-04-2020
Prospect Prospect daneză 14-09-2023
Caracteristicilor produsului Caracteristicilor produsului daneză 14-09-2023
Raport public de evaluare Raport public de evaluare daneză 08-04-2020
Prospect Prospect germană 14-09-2023
Caracteristicilor produsului Caracteristicilor produsului germană 14-09-2023
Raport public de evaluare Raport public de evaluare germană 08-04-2020
Prospect Prospect estoniană 14-09-2023
Caracteristicilor produsului Caracteristicilor produsului estoniană 14-09-2023
Raport public de evaluare Raport public de evaluare estoniană 08-04-2020
Prospect Prospect greacă 14-09-2023
Caracteristicilor produsului Caracteristicilor produsului greacă 14-09-2023
Raport public de evaluare Raport public de evaluare greacă 08-04-2020
Prospect Prospect franceză 14-09-2023
Caracteristicilor produsului Caracteristicilor produsului franceză 14-09-2023
Raport public de evaluare Raport public de evaluare franceză 08-04-2020
Prospect Prospect italiană 14-09-2023
Caracteristicilor produsului Caracteristicilor produsului italiană 14-09-2023
Raport public de evaluare Raport public de evaluare italiană 08-04-2020
Prospect Prospect letonă 14-09-2023
Caracteristicilor produsului Caracteristicilor produsului letonă 14-09-2023
Raport public de evaluare Raport public de evaluare letonă 08-04-2020
Prospect Prospect lituaniană 14-09-2023
Caracteristicilor produsului Caracteristicilor produsului lituaniană 14-09-2023
Raport public de evaluare Raport public de evaluare lituaniană 08-04-2020
Prospect Prospect maghiară 14-09-2023
Caracteristicilor produsului Caracteristicilor produsului maghiară 14-09-2023
Raport public de evaluare Raport public de evaluare maghiară 08-04-2020
Prospect Prospect malteză 14-09-2023
Caracteristicilor produsului Caracteristicilor produsului malteză 14-09-2023
Raport public de evaluare Raport public de evaluare malteză 08-04-2020
Prospect Prospect olandeză 14-09-2023
Caracteristicilor produsului Caracteristicilor produsului olandeză 14-09-2023
Raport public de evaluare Raport public de evaluare olandeză 08-04-2020
Prospect Prospect poloneză 14-09-2023
Caracteristicilor produsului Caracteristicilor produsului poloneză 14-09-2023
Raport public de evaluare Raport public de evaluare poloneză 08-04-2020
Prospect Prospect portugheză 14-09-2023
Caracteristicilor produsului Caracteristicilor produsului portugheză 14-09-2023
Raport public de evaluare Raport public de evaluare portugheză 08-04-2020
Prospect Prospect română 14-09-2023
Caracteristicilor produsului Caracteristicilor produsului română 14-09-2023
Raport public de evaluare Raport public de evaluare română 08-04-2020
Prospect Prospect slovacă 14-09-2023
Caracteristicilor produsului Caracteristicilor produsului slovacă 14-09-2023
Raport public de evaluare Raport public de evaluare slovacă 08-04-2020
Prospect Prospect slovenă 14-09-2023
Caracteristicilor produsului Caracteristicilor produsului slovenă 14-09-2023
Raport public de evaluare Raport public de evaluare slovenă 08-04-2020
Prospect Prospect finlandeză 14-09-2023
Caracteristicilor produsului Caracteristicilor produsului finlandeză 14-09-2023
Raport public de evaluare Raport public de evaluare finlandeză 08-04-2020
Prospect Prospect suedeză 14-09-2023
Caracteristicilor produsului Caracteristicilor produsului suedeză 14-09-2023
Raport public de evaluare Raport public de evaluare suedeză 08-04-2020
Prospect Prospect norvegiană 14-09-2023
Caracteristicilor produsului Caracteristicilor produsului norvegiană 14-09-2023
Prospect Prospect islandeză 14-09-2023
Caracteristicilor produsului Caracteristicilor produsului islandeză 14-09-2023
Prospect Prospect croată 14-09-2023
Caracteristicilor produsului Caracteristicilor produsului croată 14-09-2023
Raport public de evaluare Raport public de evaluare croată 08-04-2020

Căutați alerte legate de acest produs

Vizualizați istoricul documentelor